The genes involved in DNA repair system play a crucial role in the protection against mutations . It 
INTRODUCTION
Breast cancer remains the most frequent cancer and the second leading cause of cancer death among women in the world [1] . In Egypt, It accounts for nearly 35.1% of cancers among the Egypt National Cancer Institute patients [2] with an ageadjusted incidence rate of 49.6/100 000 population [3] and an increase of about 11 folds in breast cancer incidence rate between 1972 and 2001 [4] . Cells of the body constantly exposed to mutagenic assault from radiation, chemical carcinogens, alcohol, estrogen, and diet, which produce reactive oxygen species, oxidized bases, bulky DNA adducts, and DNA strand breaks. Unrepaired or misrepaired DNA may lead to deletions, amplifications, and/or mutations of critical genes that contribute to breast carcinogenesis [5] . There are multiple pathways to repair the different types of DNA damage and maintain genomic integrity. Among these pathways is nucleotide excision repair (NER) pathway that repairs a wide variety of DNA damage, including cross-links, oxidative damage and bulky adducts and the base excision repair (BER) pathway that repair small lesions such as oxidized or reduced bases, fragmented or non bulky adducts, and lesions caused by methylating agents [6] . There are over 100 identified DNA repair genes (protecting genes) and most of them are known to have genetic variation in humans [7] . DNA repair gene polymorphisms may alter the protein function and cause reduction in DNA repair capacity that may lead to genetic instability and carcinogenesis [8, 9] . The XPD (xeroderma pigmentosium group D) protein participates in NER as it represent an integral member of the basal transcription factor BTF2/TFIIH complex, which is a multi-protein with functions including transcription, NER, transcription-coupled repair, apoptosis, and cell cycle regulation. Also, the XPD gene product has an ATP-dependent DNA helicase activity [10] . Single nucleotide polymorphisms (SNPs) have been identified in several exons of the XPD gene (NER), among which one in codon 312 of exon 10 and the other in codon 751 of exon 23 are commonly studied and result in amino acid changes (Asp312Asn and Lys751Gln, respectively)
[11] . These polymorphisms are associated with lower DNA repair capacity and a higher level of DNA adducts 
SUBJECTS & METHODS

Subjects:
The EDTA-blood samples were obtained from all participants, coded and analyzed in a blind manner for genomic DNA extraction using QIAGEN genomic DNA extraction kit (QIAGEN, Clinilab, Egypt) as described in the user manual. The quality of the genomic DNA was tested using agarose gel electrophoresis.
Samples were genotyped for detecting SNP OF XPD codon 312 and XRCC1 codon 399 in genomic DNA.PCR, for both polymorphisms, was performed in a final volume of 25 µl containing 100 ng of genomic DNA, 1X PCR mix (20mM Tris-HCl, pH 8.3, 50mM KCl, 1.5mM MgCl 2 , 0.3mM dNTPs and 2U Taq DNA polymerase) and 0.2 μM of each primer .The amplification was carried out using a PTC-100 thermal cycler (MJ Research, Inc., Watertown, Massachusetts, USA).
A tetra-primer amplification refractory mutation system (ARMS)-polymerase chain reaction (PCR) assay was used for detection of XPD codon 312 polymorphism as described by Rybicki et al. (2004) [17] , The ARMS assay is an allele-specific PCR method that uses two primers, each with the 3′ terminal base complementary to one of the alleles to be identified. An internal control primer pair was included in each reaction (ARMSA: 5′-CCC ACC TTC CCC TCT CTC CAG GCA AAT GGG-3′; ARMSB: 5′-GGG CCT CAG TCC CAA CAT GGC TAA GAG GTG-3′) at a 1:5 dilution relative to the allele-specific primers. A 150-bp PCR fragment was generated with the following primers: reverse primer 5′-CAG GAT CAA AGA GAC AGA CGA GCA GCG C-3′; G allele forward specific primer 5′-GTC GGG GCT CAC CCT GCA GCA CTT CGG C-3′; A allele forward specific primer 5′-GTC GGG GCT CAC CCT GCA GCA CTT CGA T-3′. Cycling conditions were initial denaturation of 94 °C for 5 min, followed by 35 cycles of 30 s at 94 °C, 30 s at 61 °C and 50 s at 72 °C and finally 7 min at 72 °C.
The amplified products were analyzed on 2% agarose gels stained with ethidium bromide. Genotypes were typed as GG and AA depending on the development of bands when primers specific for allele G (as GG) or allele A (as AA) were used. Samples were typed as heterozygotes (GA) when bands were seen with both the primers (Fig. 1 [18] . The extracted DNA was amplified with the four primers by 'F1, 5′-TCC CTG CGC CGC TGC AGT TTC T-3′; R1, 5′-TGG CGT GTG AGG CCT TAC CTC C-3′; F2, 5′-TCG GCG GCT GCC CTC CCA-3′; and R2, 5′-AGC CCT CTG TGA CCT CCC AGG C-3′. PCR conditions were 1-min denaturation at 94°C followed by 30 cycles of 94°C for 1 min, 59°C for 1 min, and 72°C for 1 min, with a 10-min extension at 72°C. Primer pairs F1 and R1 for the G allele (399Arg) and F2 and R2 for the A allele (399Gln) produced allele-specific bands of 447-and 222-bp, respectively, as well as a 630-bp common band (Fig. 2) .
Statistical Analysis
Statistical analysis was done using the Statistical Package for Social Sciences version 11 (SPSS Inc., Chicago, USA). The significance of association between the observed and expected number of the genotypes for a population in the HardyWeinberg equilibrium was analyzed using the Pearson's two-sided chisquare test. The differences of genotype and allele frequencies between the cases and controls were determined using Chi-square(X 2 ) test. The associations between genotypes and BC risk were analyzed by calculating the crude Odds Ratios (OR) and 95% Confidence Intervals (CI) by logistic regression method. The adjusted odds ratio was calculated using the multivariate logistic regression method with an adjustment for age. P value of <0.05 was considered statistically significant.
RESULTS
CEA and CA15.3 assay and BC risks
In the breast cancer patients the CEA ranged from 4.5 to 8.5 ng/ml, with a mean value ± SD (6.7±0.13 ng/ml), while in the control group CEA ranged from 2.5-3.1 ng/ml with a mean value of 2.8±0.01 ng/ml, there was significant difference as regard CEA levels (P<0.001).
As regard CA15.3 there was significant difference between breast cancer cases and the control group (P<0.001), as the mean level of CA15.3 ± SD in the cases was 66.24±1.27 IU/l with a range of 42-86 IU/l, while in the control group CA15.3 ranged from 2.5 to 3.1 IU/l, with a mean value ± SD of 2.8±0.02 IU/l. Table 2   Table 2 : The serum levels of CEA and CA15.3 in breast cancer patients (n=100) and in the control subjects (n=100). 
Parameters
XPD Asp312Asn polymorphism and BC risk
The genotype frequencies of homozygous (GG), heterozygous (AG), and homozygous mutated (AA) were 12%, 45%, and 43% in patients with BC respectively; and 25%, 50%, and 25% in controls respectively.
The frequency of A allele was 65.5% in BC patients and 50% in controls. These data suggest that the A allele was significantly associated with an increased risk of BC (ORadj: 1.8, 95% CI, 1.2-2.8) (P=0.002). The homozygous mutant genotype (AA) significantly increased the risk of BC (ORadj: 3.5, 95% CI, 1.5-8.3) (P=0.003) in comparison with those with (GG) genotype. However, the (AG) genotype showed no significant difference between patients and control groups (p=0.08) (ORadj: 1.8, 95% CI, 0.8-4.1).
AA genotype increased the risk of BC by (2.26 CI = 1.2-4.1) between pts and control group. The distribution of XPD Asp312Asn allele and genotype frequencies in breast cancer patients and the control subjects are represented in Table 3 . 
XRCC1 A399G polymorphism and BC risk
The genotype frequencies of homozygous (AA), heterozygous (AG), and homozygous mutated (GG) were 37%, 51%, and 12% in patients with BC respectively; and 50%, 40%, and 10% in controls respectively.
The frequency of G (mutant) allele was 37.5% in BC patients and 30% in controls.
However, that difference didn't show statistical significant difference between patients and control groups (ORadj: 1.4, 95% CI, 0.9-2.1) (P=0.06). The homozygous mutant genotype (GG) and the heterozygous (AG) genotype showed no significant difference in patients and control groups (p=0.3) (ORadj: 1.6 95% CI, 0.6-4.1).and (p=0.07) (ORadj: 1.7 95% CI, 0.9-3.1) in relation to (AA) genotype. The distribution of XRCC1 A399G allele and genotype frequencies in breast cancer patients and the control subjects are represented in Table 4 . 
DISCUSSION
One of the most commonly diagnosed cancers over the world is the Breast cancer, but its etiology is still largely unknown. Several environmental factors, as radiation, diet, smoking, and endogenous or exogenous estrogens, are associated with DNA damage. Unrepaired or misrepaired DNA results in gene mutations, chromosomal alterations, genomic instability and carcinogenesis [19] . Earlier studies have demonstrated a strong association of higher levels of DNA damage and deficient DNA repair capacity in breast cancer patients [20, 21] . Genetic polymorphisms on DNA repair genes are very common events, and there are conflicting reports on the influence of these polymorphisms on DNA repair capacity and cancer susceptibility [22] [23] [24] .
The cause of breast cancer is complicated and can not be explained by means of only a single selected marker. Therefore, the goal of the present study was to examine the relation of two DNA repair genes XPD and XRCC1 polymorphisms with the risk of BC in Eastern Egyptian females .Also to determine the gene-gene interaction aiming to increase our understanding of the interaction between potential carcinogenic environmental exposure and genetic factors in the pathogenesis and predisposition to BC disease risk.
As regard to XPD codon 312 polymorphism, our results revealed that the frequencies of AA genotypes and A allele were significantly higher in the breast cancer patients than in the normal individuals (p≤0.003,p≤0.002 respectively). It was also found that participants homozygous Asn at XPD Asp312Asn had 3.5-fold higher risk of breast cancer.
Our [36] in their study on XRCC1 codon 399 polymorphism in sporadic and familial breast cancer patients.
Although the effect of an individual SNP is generally small, it is believed that the genetic effect of combinations of functionally relevant SNPs may additively or synergistically contribute to increased breast cancer risk. So, we studied the combined polymorphism of XPD and XRCC1 genes. To the best of our knowledge, there are no previous reports available regarding the association between combined polymorphism of XPD and XRCC1 genes and breast cancer from Egypt. Our results revealed that only combination of AA(XPD)+ AG (XRCC1) might increase the risk of breast cancer (OR 3.36 CI 0.9 ---11.3) (p≤0.04). However, these results need more investigation to study genegene interactions and its relation to breast cancer susceptibility aiming to identify individuals at increased risk of breast cancer and develop preventive strategies . 
